2020年12月
Aminoglycoside Resistance (Review)
Infectious Disease Clinics of North America
- ,
- ,
- 巻
- 34
- 号
- 4
- 開始ページ
- 887
- 終了ページ
- 902
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1016/j.idc.2020.06.002
- 出版者・発行元
- Elsevier BV
The clinical usefulness of aminoglycosides has been revisited as an effective choice against β-lactam-resistant and fluoroquinolone-resistant gram-negative bacterial infections. Plazomicin, a next-generation aminoglycoside, was introduced for the treatment of complicated urinary tract infections and acute pyelonephritis. In contrast, bacteria have resisted aminoglycosides, including plazomicin, by producing 16S ribosomal RNA (rRNA) methyltransferases (MTases) that confer high-level and broad-range aminoglycoside resistance. Aminoglycoside-resistant 16S rRNA MTase-producing gram-negative pathogens are widespread in various settings and are becoming a grave concern. This article provides up-to-date information with a focus on aminoglycoside-resistant 16S rRNA MTases.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.idc.2020.06.002
- ISSN : 0891-5520
- PubMed ID : 33011054